Local biopharmaceutical firm Adimmune Corp (國光生技) made public on Friday its intention to become the only supplier in Taiwan of a human vaccine against A(H1N1), a new influenza strain that broke out in Mexico in April.
Adimmune spokesman Kao Sheng-kai (高勝凱) made the declaration after a tender held by the Department of Health (DOH) earlier in the day for 5 million doses of the vaccine failed because only Adimmune submitted a bid.
The law governing governmental tenders requires that at least three companies submit bids for a tender to be valid.
SECOND ROUND
The DOH, however, will open a second tender next week that according to the Government Procurement Act (政府採購法) will not require a minimum number of bidders or a preset price range, Centers for Disease Control Deputy Director-General Lin Ding (林頂) said.
Kao said that his company, also known as Kuo Kwang Biotechnology Co, intends to vie for the business and become the government’s main supplier of the vaccine.
Foreign suppliers, already unable to meet demand in international markets and unlikely to be able to comply with the government’s targeted October delivery date, have not shown any desire to participate in tenders for the (A)H1N1 vaccine.
PRICE
Kao said the price of the vaccine for swine flu, which in recent months has spread around the world, has been on the rise because of increasing demand, including the US requirement of some 600 million doses.
Using the case of Novartis AG as an example, Kao said that the Switzerland-based drug company sold the vaccine at between US$8 and US$10 per dose to early buyers, but that this has recently increased to more than US$10 per dose.
Adimmune general manager Ignatius Wei (魏逸之) said the company’s price for the vaccine would be below US$10 per dose, but Kao said on Friday that the final price would be decided by the company’s board of directors.
CONDITIONS
The DOH said the government had planned to purchase the vaccine at a price of NT$200 per dose, but it would be allowed to raise its purchase price in the second tender.
The only private human vaccine manufacturing company in Taiwan said that it has purchased 8 million chicken eggs to produce the human vaccine against (A)H1N1 using chicken embryos.
Kao indicated that the company has begun the process of producing more than 1.5 doses from one egg, and he estimated Adimmune could produce between 7.5 million and 10 million doses of the vaccine with its available egg stocks.
DOSES
The DOH would purchase 10 million doses of the (A)H1N1 virus vaccine, 5 million doses of seasonal flu vaccine, and 900,000 doses of the antiviral drug Relenza this year to strengthen its anti-pandemic arsenal, Lin said.
So far, the DOH has secured 2.28 million doses of vaccine against seasonal flu, including 400,000 doses for children, Lin said.
Intel Corp chief executive officer Lip-Bu Tan (陳立武) is expected to meet with Taiwanese suppliers next month in conjunction with the opening of the Computex Taipei trade show, supply chain sources said on Monday. The visit, the first for Tan to Taiwan since assuming his new post last month, would be aimed at enhancing Intel’s ties with suppliers in Taiwan as he attempts to help turn around the struggling US chipmaker, the sources said. Tan is to hold a banquet to celebrate Intel’s 40-year presence in Taiwan before Computex opens on May 20 and invite dozens of Taiwanese suppliers to exchange views
Application-specific integrated circuit designer Faraday Technology Corp (智原) yesterday said that although revenue this quarter would decline 30 percent from last quarter, it retained its full-year forecast of revenue growth of 100 percent. The company attributed the quarterly drop to a slowdown in customers’ production of chips using Faraday’s advanced packaging technology. The company is still confident about its revenue growth this year, given its strong “design-win” — or the projects it won to help customers design their chips, Faraday president Steve Wang (王國雍) told an online earnings conference. “The design-win this year is better than we expected. We believe we will win
Chizuko Kimura has become the first female sushi chef in the world to win a Michelin star, fulfilling a promise she made to her dying husband to continue his legacy. The 54-year-old Japanese chef regained the Michelin star her late husband, Shunei Kimura, won three years ago for their Sushi Shunei restaurant in Paris. For Shunei Kimura, the star was a dream come true. However, the joy was short-lived. He died from cancer just three months later in June 2022. He was 65. The following year, the restaurant in the heart of Montmartre lost its star rating. Chizuko Kimura insisted that the new star is still down
While China’s leaders use their economic and political might to fight US President Donald Trump’s trade war “to the end,” its army of social media soldiers are embarking on a more humorous campaign online. Trump’s tariff blitz has seen Washington and Beijing impose eye-watering duties on imports from the other, fanning a standoff between the economic superpowers that has sparked global recession fears and sent markets into a tailspin. Trump says his policy is a response to years of being “ripped off” by other countries and aims to bring manufacturing to the US, forcing companies to employ US workers. However, China’s online warriors